Chfr and paclitaxel sensitivity of ovarian cancer

Andrea E. Wahner Hendrickson, Daniel W. Visscher, Xiaonan Hou, Krista M. Goergen, Hunter J. Atkinson, Thomas G. Beito, Vivian Negron, Wilma L. Lingle, Amy K. Bruzek, Rachel M. Hurley, Jill M. Wagner, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Melissa C. Larson, Matthew J. Maurer, Kimberly R. Kalli, Ann L. Oberg, S. John Weroha, Scott H. Kaufmann

Research output: Contribution to journalArticlepeer-review


The poly(ADP‐ribose) binding protein CHFR regulates cellular responses to mitotic stress. The deubiquitinase UBC13, which regulates CHFR levels, has been associated with better overall survival in paclitaxel‐treated ovarian cancer. Despite the extensive use of taxanes in the treatment of ovarian cancer, little is known about expression of CHFR itself in this disease. In the present study, tissue microarrays containing ovarian carcinoma samples from 417 women who underwent initial surgical debulking were stained with anti‐CHFR antibody and scored in a blinded fashion. CHFR levels, expressed as a modified H‐score, were examined for association with histology, grade, time to progression (TTP) and overall survival (OS). In addition, patient‐derived xenografts from 69 ovarian carcinoma patients were examined for CHFR expression and sensitivity to paclitaxel monotherapy. In clinical ovarian cancer specimens, CHFR expression was positively associated with serous histology (p = 0.0048), higher grade (p = 0.000014) and higher stage (p = 0.016). After correction for stage and debulking, there was no significant association between CHFR staining and overall survival (p = 0.62) or time to progression (p = 0.91) in patients with high grade serous cancers treated with platinum/taxane chemotherapy (N = 249). Likewise, no association between CHFR expression and paclitaxel sensitivity was observed in ovarian cancer PDXs treated with paclitaxel monotherapy. Accordingly, differences in CHFR expression are unlikely to play a major role in paclitaxel sensitivity of high grade serous ovarian cancer.

Original languageEnglish (US)
Article number6043
Issue number23
StatePublished - Dec 1 2021


  • CHFR
  • Ovarian cancer
  • Patient‐derived xenografts
  • Taxanes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Chfr and paclitaxel sensitivity of ovarian cancer'. Together they form a unique fingerprint.

Cite this